CJC-1295 with DAC

Step	Weeks	Dose	Purpose
Weeks 1–2	—	1 mg	Assess response, check water retention
Weeks 3–16	—	1–2 mg	Sustained IGF-1 elevation protocol

Beginner Protocol

Intermediate Protocol

Advanced Protocol

Reconstitution and handling notes

Stacking Notes

Additional Dosage Notes

Primary clinical dataset

• Teichman et al., 2006, J Clin Endocrinol Metab - Phase 1, 50 healthy adults, single-dose and multi-dose. Doses: 30, 60, 90 mcg/kg SC. Established the albumin-conjugation mechanism, dose-response, and sustained IGF-1 elevation. 60 mcg/kg produced peak GH of 2-10x baseline with 6-14 day duration; multi-weekly dosing sustained IGF-1 elevation 1.5-3x baseline for up to 28 days.

• [Ionescu & Frohman, 2006, J Clin Endocrinol Metab] - Companion Phase 1 pharmacokinetic/pharmacodynamic study. Confirmed dose-dependent PK and showed that pulsatile GH secretion persists during continuous stimulation - DAC raises basal (trough) and mean GH while the IGF-1 response settles into a plateau.

Why it didn't advance

Clinical development halted at Phase 2. The publicly available information does not detail specific reasons, but expert commentary points to:

• Concerns about chronic non-pulsatile GH elevation
• Competing development of tesamorelin (shorter-acting GHRH analog) for HIV lipodystrophy
• Commercial challenges in the GH-axis space
• Post-acquisition prioritization changes at ConjuChem

Extrapolation from sermorelin

• [Tesar, 2010] - Sermorelin (native GRF 1-29) clinical review; provides insight into long-term GHRH-receptor agonist safety

IGF-1 cancer safety signal

• Renehan et al., 2004, Lancet - Meta-analysis: higher IGF-1 associated with prostate, colorectal, premenopausal breast cancer. Directly relevant given DAC produces higher sustained IGF-1 than non-DAC form.
• [Chan et al., 1998, Science] - Prostate cancer association with elevated IGF-1.

GH and body composition

• Blackman et al., 2002, JAMA - rhGH in healthy older adults: 1-3 kg lean mass gain, 2-3 kg fat loss, significant side-effect burden. This is the ceiling for what sustained GH elevation can achieve.
• [Liu et al., 2007, Ann Intern Med] - Systematic review: modest body composition benefit with meaningful side effects.

Critical illness safety signal

• [Takala et al., 1999, NEJM] - Exogenous GH in critically-ill patients doubled mortality. Not directly applicable to healthy outpatient use but informs the general principle: sustained non-pulsatile GH elevation can have unexpected adverse effects.

What is NOT in the dataset

• No Phase 3 trial of CJC-1295 DAC in any indication
• No long-term (>1 year) safety data in healthy adults
• No head-to-head comparison of DAC vs non-DAC form on any clinical endpoint
• No cancer incidence data (surveillance-quality) in CJC-1295 users
• No longevity endpoint data (and GH/IGF-1 biology argues against longevity benefit)

Evidence weighting

Strong: single-dose pharmacokinetics, acute GH/IGF-1 response magnitude. Moderate: 1-3 month tolerability in healthy adults. Weak: long-term safety, long-term benefit, cancer surveillance data.

Expected / benign

• Injection-site reaction — redness, slight swelling, itching at the weekly injection
• Facial flushing / warmth post-injection, sometimes lasting hours (longer than with MOD-GRF 1-29)
• Vivid dreams — very common in first weeks
• Mild nausea at higher doses initially
• Hunger increase — less than ghrelin-receptor agonists

Common (dose-related)

• Water retention / peripheral edema — more prominent than with MOD-GRF 1-29 due to sustained GH elevation
• Finger / wrist stiffness, paresthesias — carpal tunnel symptoms, dose-responsive
• Fatigue or lethargy during first 1-2 weeks — resolves as axis stabilizes
• Elevated fasting glucose — GH is counter-regulatory to insulin; more common with DAC than MOD-GRF 1-29
• Mild insulin resistance — reflected in HOMA-IR rise on fasting insulin + glucose

Less common but clinically important

• Significant carpal tunnel syndrome — may require dose reduction or discontinuation
• Joint pain / arthralgia — knees, hips, fingers
• Headache — persistent, usually resolves with dose reduction
• Sleep changes — ironically, sustained GH can disrupt the natural GH pulse pattern and worsen sleep architecture

Dose-related serious

• Glucose intolerance / overt type 2 diabetes — sustained GH elevation is a known cause; particular risk in predisposed individuals
• Acromegaly-like features — theoretical at chronic high-dose use; not documented at therapeutic doses
• Peripheral neuropathy from sustained edema / compression
• Potential pro-tumorigenic effect — sustained high IGF-1 epidemiologically associated with increased cancer risk (Renehan et al., 2004)

Absolute contraindications

• Active malignancy (any type)
• History of cancer within 5 years
• Diabetic retinopathy
• Pregnancy and lactation
• Children with open growth plates
• Critical illness (ICU care) — GH increased mortality in this population ([Takala 1999])
• Severe uncontrolled type 2 diabetes

Relative contraindications

• Type 2 diabetes (well-controlled)
• Obstructive sleep apnea
• Intracranial pathology
• Severe hypothyroidism
• Family history of acromegaly

Particular safety concerns specific to DAC variant (vs non-DAC)

• Sustained IGF-1 elevation: greater cancer-association concern
• No "off" period in receptor exposure: higher desensitization risk
• Limited ability to adjust dose mid-week if side effects occur (half-life is long)
• Cannot be stopped rapidly in emergency (washout 2-3 weeks to baseline)

Lab monitoring essential

• Baseline: IGF-1, IGFBP-3, fasting glucose, HbA1c, CBC, CMP
• Follow-up: IGF-1 at 4 weeks and 12 weeks; fasting glucose and HbA1c quarterly
• Target: IGF-1 at upper-normal for age, NOT supraphysiologic